John Newman
Stock Analyst at Canaccord Genuity
(1.45)
# 2,888
Out of 4,784 analysts
87
Total ratings
38.67%
Success rate
-10.15%
Average return
Main Sectors:
Stocks Rated by John Newman
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ALLO Allogene Therapeutics | Maintains: Buy | $14 | $1.55 | +803.23% | 3 | Mar 14, 2025 | |
| BNTX BioNTech SE | Maintains: Buy | $171 | $94.95 | +80.56% | 8 | Mar 11, 2025 | |
| ATRA Atara Biotherapeutics | Maintains: Buy | $17 | $6.53 | +160.34% | 5 | Mar 11, 2025 | |
| MRKR Marker Therapeutics | Initiates: Buy | $8 | $1.27 | +529.92% | 1 | Mar 5, 2025 | |
| CADL Candel Therapeutics | Maintains: Buy | $20 → $25 | $5.95 | +320.52% | 2 | Feb 26, 2025 | |
| REGN Regeneron Pharmaceuticals | Initiates: Hold | $165 | $637.36 | -74.11% | 16 | Dec 17, 2024 | |
| MCRB Seres Therapeutics | Maintains: Buy | $10 | $0.72 | +1,286.96% | 9 | Nov 14, 2024 | |
| DCTH Delcath Systems | Maintains: Buy | $21 | $13.15 | +59.70% | 1 | Oct 18, 2024 | |
| ACLX Arcellx | Maintains: Buy | $85 → $115 | $67.96 | +69.22% | 8 | Oct 17, 2024 | |
| ACET Adicet Bio | Maintains: Buy | $19 → $8 | $0.83 | +863.62% | 6 | Sep 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $67 | $44.61 | +50.19% | 2 | Jul 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $38 → $43 | $14.54 | +195.74% | 1 | Jul 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $450 → $180 | $3.32 | +5,321.69% | 1 | May 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $12 → $11 | $4.95 | +122.22% | 1 | May 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $5 | $0.60 | +733.33% | 2 | Jun 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $52 → $44 | $30.28 | +45.31% | 9 | Feb 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $1,720 → $400 | $4.08 | +9,703.92% | 4 | Aug 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $210 → $220 | $8.28 | +2,557.00% | 3 | Jun 13, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $30 → $38 | $15.25 | +149.18% | 2 | Oct 17, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $12 → $27 | $6.67 | +304.80% | 2 | Sep 13, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Speculative Buy | n/a | $8.29 | - | 1 | Sep 13, 2017 |
Allogene Therapeutics
Mar 14, 2025
Maintains: Buy
Price Target: $14
Current: $1.55
Upside: +803.23%
BioNTech SE
Mar 11, 2025
Maintains: Buy
Price Target: $171
Current: $94.95
Upside: +80.56%
Atara Biotherapeutics
Mar 11, 2025
Maintains: Buy
Price Target: $17
Current: $6.53
Upside: +160.34%
Marker Therapeutics
Mar 5, 2025
Initiates: Buy
Price Target: $8
Current: $1.27
Upside: +529.92%
Candel Therapeutics
Feb 26, 2025
Maintains: Buy
Price Target: $20 → $25
Current: $5.95
Upside: +320.52%
Regeneron Pharmaceuticals
Dec 17, 2024
Initiates: Hold
Price Target: $165
Current: $637.36
Upside: -74.11%
Seres Therapeutics
Nov 14, 2024
Maintains: Buy
Price Target: $10
Current: $0.72
Upside: +1,286.96%
Delcath Systems
Oct 18, 2024
Maintains: Buy
Price Target: $21
Current: $13.15
Upside: +59.70%
Arcellx
Oct 17, 2024
Maintains: Buy
Price Target: $85 → $115
Current: $67.96
Upside: +69.22%
Adicet Bio
Sep 11, 2024
Maintains: Buy
Price Target: $19 → $8
Current: $0.83
Upside: +863.62%
Jul 25, 2024
Maintains: Buy
Price Target: $67
Current: $44.61
Upside: +50.19%
Jul 3, 2024
Maintains: Buy
Price Target: $38 → $43
Current: $14.54
Upside: +195.74%
May 16, 2024
Maintains: Buy
Price Target: $450 → $180
Current: $3.32
Upside: +5,321.69%
May 9, 2024
Maintains: Buy
Price Target: $12 → $11
Current: $4.95
Upside: +122.22%
Jun 23, 2023
Reiterates: Buy
Price Target: $5
Current: $0.60
Upside: +733.33%
Feb 16, 2022
Maintains: Buy
Price Target: $52 → $44
Current: $30.28
Upside: +45.31%
Aug 10, 2021
Downgrades: Hold
Price Target: $1,720 → $400
Current: $4.08
Upside: +9,703.92%
Jun 13, 2018
Maintains: Buy
Price Target: $210 → $220
Current: $8.28
Upside: +2,557.00%
Oct 17, 2017
Maintains: Buy
Price Target: $30 → $38
Current: $15.25
Upside: +149.18%
Sep 13, 2017
Maintains: Buy
Price Target: $12 → $27
Current: $6.67
Upside: +304.80%
Sep 13, 2017
Downgrades: Speculative Buy
Price Target: n/a
Current: $8.29
Upside: -